Background & relevance

Hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is the most common subset of breast cancers. In the metastatic setting, novel therapies have expanded and shifted the treatment landscape.

Regulatory approval status of endocrine and targeted therapies for HR+ HER2- advanced or metastatic breast cancer (status 23 August 2023)